1
|
Kim JE, Lee EJ, Wu Y, Kang YG, Shin JW. The combined effects of hierarchical scaffolds and mechanical stimuli on ex vivo expansion of haematopoietic stem/progenitor cells. Artif Cells Nanomed Biotechnol 2019; 47:586-593. [PMID: 30831031 DOI: 10.1080/21691401.2019.1573180] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
We describe the ex vivo expansion of haematopoietic stem/progenitor cells (HSPCs) with consideration of their eventual in-vivo niche. We firstly fabricated hierarchically structured scaffolds (lattices derived via three-dimensional plotting combined with electrospun submicron fibers coated with vitronectin to increase cell affinity). We also applied intermittent hydrostatic pressure (IHP) to mimic the physical environment of the in vivo niche. In the absence of mechanical stimuli, the cell phenotype (CD34+, CD34+CD38-) remained excellent in the vitronectin-treated group. Two IHP regimens were tested; optimally, cells were pressurized (20 kPa) for 2 min and then rested for 13 min. On day 7 of culture, the total cell number had increased 21.2-fold and that of CD34+ cells 10.94-fold. CD34+ and CD34+CD38- cells constituted 44.50 and 44.07% of total cells, respectively. Colony-forming counts and the long-term culture-initiating cell assay showed that clonogenic potential was greatly improved under our experimental conditions. Scaffolds with hierarchical structures were valuable in this context. Furthermore, ex vivo expansion of HSPCs was improved by physical stimulation.
Collapse
Affiliation(s)
- Ji Eun Kim
- a Department of Biomedical Engineering , Inje University , Gimhae , Gyeongsangnam-do , Republic of Korea
| | - Eun Jin Lee
- a Department of Biomedical Engineering , Inje University , Gimhae , Gyeongsangnam-do , Republic of Korea
| | - Yanru Wu
- b Department of Health Science and Technology , Inje University , Gimhae , Gyeongsangnam-do , Republic of Korea
| | - Yun Gyeong Kang
- a Department of Biomedical Engineering , Inje University , Gimhae , Gyeongsangnam-do , Republic of Korea
| | - Jung-Woog Shin
- a Department of Biomedical Engineering , Inje University , Gimhae , Gyeongsangnam-do , Republic of Korea.,c Cardiovascular and Metabolic Disease Center/Institute of Aged Life Redesign/UHARC , Inje University , Gimhae , Republic of Korea
| |
Collapse
|
2
|
Chen X, Han Y, Zhang B, Liu Y, Wang S, Liao T, Deng Z, Fan Z, Zhang J, He L, Yue W, Li Y, Pei X. Caffeic acid phenethyl ester promotes haematopoietic stem/progenitor cell homing and engraftment. Stem Cell Res Ther 2017; 8:255. [PMID: 29116023 PMCID: PMC5678809 DOI: 10.1186/s13287-017-0708-x] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2017] [Revised: 08/24/2017] [Accepted: 10/23/2017] [Indexed: 11/24/2022] Open
Abstract
Background Several studies have suggested that caffeic acid phenethyl ester (CAPE) can induce the expression of hypoxia inducible factor-1α (HIF-1α) protein. We determined whether CAPE has a novel function in improving the homing and engraftment of haematopoietic stem/progenitor cells (HSPCs) by regulating HIF-1α gene expression in the bone marrow (BM) niche. Methods For survival experiments, lethally irradiated C57BL/6 mice were injected with a low number of BM mononuclear cells (MNCs) and CAPE according to the indicated schedule. Homing efficiency analysis was conducted using flow cytometry and colony-forming unit (CFU) assays. The influence of intraperitoneal injection of CAPE on short-term and long-term engraftment of HSPCs was evaluated using competitive and non-competitive mouse transplantation models. To investigate the mechanism by which CAPE enhanced HSPC homing, we performed these experiments including Q-PCR, western blot, immunohistochemistry and CFU assays after in-vivo HIF-1α activity blockade. Results CAPE injection significantly increased the survival rate of recipient mice after lethal irradiation and transplantation of a low number of BM MNCs. Using HSPC homing assays, we found that CAPE notably increased donor HSPC homing to recipient BM. The subsequent short-term and long-term engraftment of transplanted HSPCs was also improved by the optimal schedule of CAPE administration. Mechanistically, we found that CAPE upregulated the expression of HIF-1α, vascular endothelial growth factor-A (VEGF-A) and stromal cell-derived factor 1α (SDF-1α). The HIF-1α inhibitor PX-478 blocked CAPE-enhanced HSPC homing, which supported the idea that HIF-1α is a key target of CAPE. Conclusions Our results showed that CAPE administration facilitated HSPC homing and engraftment, and this effect was primarily dependent on HIF-1α activation and upregulation of SDF-1α and VEGF-A expression in the BM niche. Electronic supplementary material The online version of this article (doi:10.1186/s13287-017-0708-x) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Xiaofang Chen
- School of Laboratory Medicine and Biotechnology, Southern Medical University, No. 1838 Guangzhou Avenue North, Baiyun District, Guangzhou, 510515, China.,Stem Cell and Regenerative Medicine Lab, Beijing Institute of Transfusion Medicine, No. 27 Taiping Road, Haidian District, Beijing, 100850, China.,South China Institute of Biomedicine, No. 1 Luoxuan 4th Road, Haizhu District, Guangzhou, 510005, China
| | - Yi Han
- Stem Cell and Regenerative Medicine Lab, Beijing Institute of Transfusion Medicine, No. 27 Taiping Road, Haidian District, Beijing, 100850, China
| | - Bowen Zhang
- Stem Cell and Regenerative Medicine Lab, Beijing Institute of Transfusion Medicine, No. 27 Taiping Road, Haidian District, Beijing, 100850, China.,South China Institute of Biomedicine, No. 1 Luoxuan 4th Road, Haizhu District, Guangzhou, 510005, China
| | - Yiming Liu
- Stem Cell and Regenerative Medicine Lab, Beijing Institute of Transfusion Medicine, No. 27 Taiping Road, Haidian District, Beijing, 100850, China
| | - Sihan Wang
- Stem Cell and Regenerative Medicine Lab, Beijing Institute of Transfusion Medicine, No. 27 Taiping Road, Haidian District, Beijing, 100850, China.,South China Institute of Biomedicine, No. 1 Luoxuan 4th Road, Haizhu District, Guangzhou, 510005, China
| | - Tuling Liao
- Stem Cell and Regenerative Medicine Lab, Beijing Institute of Transfusion Medicine, No. 27 Taiping Road, Haidian District, Beijing, 100850, China.,South China Institute of Biomedicine, No. 1 Luoxuan 4th Road, Haizhu District, Guangzhou, 510005, China
| | - Ziliang Deng
- South China Institute of Biomedicine, No. 1 Luoxuan 4th Road, Haizhu District, Guangzhou, 510005, China.,Guangdong Medical University, No. 1 Xincheng Road, Dongguan, 523808, China
| | - Zeng Fan
- Stem Cell and Regenerative Medicine Lab, Beijing Institute of Transfusion Medicine, No. 27 Taiping Road, Haidian District, Beijing, 100850, China.,South China Institute of Biomedicine, No. 1 Luoxuan 4th Road, Haizhu District, Guangzhou, 510005, China
| | - Jing Zhang
- Stem Cell and Regenerative Medicine Lab, Beijing Institute of Transfusion Medicine, No. 27 Taiping Road, Haidian District, Beijing, 100850, China.,South China Institute of Biomedicine, No. 1 Luoxuan 4th Road, Haizhu District, Guangzhou, 510005, China
| | - Lijuan He
- Stem Cell and Regenerative Medicine Lab, Beijing Institute of Transfusion Medicine, No. 27 Taiping Road, Haidian District, Beijing, 100850, China.,South China Institute of Biomedicine, No. 1 Luoxuan 4th Road, Haizhu District, Guangzhou, 510005, China
| | - Wen Yue
- Stem Cell and Regenerative Medicine Lab, Beijing Institute of Transfusion Medicine, No. 27 Taiping Road, Haidian District, Beijing, 100850, China.,South China Institute of Biomedicine, No. 1 Luoxuan 4th Road, Haizhu District, Guangzhou, 510005, China
| | - Yanhua Li
- Stem Cell and Regenerative Medicine Lab, Beijing Institute of Transfusion Medicine, No. 27 Taiping Road, Haidian District, Beijing, 100850, China. .,South China Institute of Biomedicine, No. 1 Luoxuan 4th Road, Haizhu District, Guangzhou, 510005, China.
| | - Xuetao Pei
- School of Laboratory Medicine and Biotechnology, Southern Medical University, No. 1838 Guangzhou Avenue North, Baiyun District, Guangzhou, 510515, China. .,Stem Cell and Regenerative Medicine Lab, Beijing Institute of Transfusion Medicine, No. 27 Taiping Road, Haidian District, Beijing, 100850, China. .,South China Institute of Biomedicine, No. 1 Luoxuan 4th Road, Haizhu District, Guangzhou, 510005, China.
| |
Collapse
|
3
|
Andreone P, Catani L, Margini C, Brodosi L, Lorenzini S, Sollazzo D, Nicolini B, Giordano R, Montemurro T, Rizzi S, Dan E, Giudice V, Viganò M, Casadei A, Foschi FG, Malvi D, Bernardi M, Conti F, Lemoli RM. Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: A phase I clinical trial. Dig Liver Dis 2015; 47:1059-66. [PMID: 26427587 DOI: 10.1016/j.dld.2015.08.018] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/13/2015] [Revised: 08/24/2015] [Accepted: 08/29/2015] [Indexed: 12/11/2022]
Abstract
BACKGROUND Bone marrow stem/progenitor cells seem to be effective in liver regeneration after tissue injury. AIM To evaluate the feasibility and safety of the mobilization and reinfusion of CD133+ stem/progenitor cells in patients with end-stage liver disease. METHODS Autologous CD133+ stem/progenitor cells, mobilized with granulocyte-colony stimulating factor, were collected by leukapheresis and reinfused at increasing doses through the hepatic artery starting from 5×10(4)/kg up to 1×10(6)/kg. RESULTS 16 subjects with Model for End-stage Liver Disease (MELD) score between 17 and 25 were enrolled, 14 mobilized an adequate number of CD133+ stem/progenitor cells and 12 were reinfused. No severe adverse events related to the procedure were reported. MELD score significantly worsened during mobilization in Child Turcotte Pugh-C patients. A significant improvement of liver function was observed 2 months after reinfusion (MELD 19.5 vs. 16; P=0.045). Overall, 5 patients underwent liver transplantation within 12 months from reinfusion and 2 died because of progressive liver failure. CONCLUSIONS CD133+ stem/progenitor cells reinfusion in patients with end-stage liver disease is feasible and safe. A worsening of liver function was observed during mobilization in Child Turcotte Pugh-C patients. The temporary improvement of MELD score after reinfusion suggests that stem cells therapy may be a "bridge to transplant" approach for these patients.
Collapse
Affiliation(s)
- Pietro Andreone
- Department of Medical and Surgical Sciences, Bologna University, Bologna, Italy.
| | - Lucia Catani
- Department of Specialty Diagnostic and Experimental Medicine, Bologna University, Bologna, Italy
| | - Cristina Margini
- Department of Medical and Surgical Sciences, Bologna University, Bologna, Italy
| | - Lucia Brodosi
- Department of Medical and Surgical Sciences, Bologna University, Bologna, Italy
| | - Stefania Lorenzini
- Department of Medical and Surgical Sciences, Bologna University, Bologna, Italy
| | - Daria Sollazzo
- Department of Specialty Diagnostic and Experimental Medicine, Bologna University, Bologna, Italy
| | - Benedetta Nicolini
- Department of Specialty Diagnostic and Experimental Medicine, Bologna University, Bologna, Italy
| | - Rosaria Giordano
- Cell Factory, Unit of Cell Therapy and Cryobiology, Fondazione IRCCS Ca' Granda, Maggiore Hospital, Milano, Italy
| | | | - Simonetta Rizzi
- Department of Specialty Diagnostic and Experimental Medicine, Bologna University, Bologna, Italy
| | - Elisa Dan
- Department of Specialty Diagnostic and Experimental Medicine, Bologna University, Bologna, Italy
| | - Valeria Giudice
- Transfusion Medicine Unit, Bologna University Hospital, Policlinico S. Orsola-Malpighi, Bologna, Italy
| | - Mariele Viganò
- Department of Regenerative Medicine, Maggiore Hospital, Milano, Italy
| | - Andrea Casadei
- Zompatori Radiology Unit, Bologna University Hospital, Policlinico S. Orsola-Malpighi, Bologna, Italy
| | | | - Deborah Malvi
- "F. Addarii" Institute of Oncology and Transplantation, Bologna University Hospital, Policlinico S. Orsola-Malpighi, Bologna, Italy
| | - Mauro Bernardi
- Department of Medical and Surgical Sciences, Bologna University, Bologna, Italy
| | - Fabio Conti
- Department of Medical and Surgical Sciences, Bologna University, Bologna, Italy
| | - Roberto M Lemoli
- Haematology Clinic, Internal Medicine Department, Genoa University, Genoa, Italy
| |
Collapse
|